Kornimate/medical-research-clean huggingface dataset:
a pilot study of a community health agent-led diabetes self-management program

Conditions: Type2 Diabetes

Summary: this was a pilot study to assess the feasibility and acceptability of training community health agents in motivational interviewing in real-life primary care centers.

rates of noncommunicable diseases (ncds) such as type 2 diabetes are escalating in low and middle-income countries such as brazil. scalable primary care-based interventions are needed to improve self-management and clinical outcomes of adults with diabetes. this pilot study examines the feasibility, acceptability, and outcomes of training community health agents (chas) in motivational interviewing (mi)-based counseling for patients with poorly controlled diabetes in a primary care center in são paulo, brazil. nineteen salaried chas participated in 32 hours of training in mi and behavioral action planning. with support from booster training sessions, they used these skills in their regular monthly home visits over a 6 month period with 57 diabetes patients with baseline hba1cs \> 7.0%. the primary outcome was patients' reports of the quality of diabetes care as measured by the portuguese version of the patient assessment of chronic illness care (pacic) scale. secondary outcomes included changes in patients' reported diabetes self-management behaviors and in a1c, blood pressure, cholesterol and triglycerides. chas' fidelity to and experiences with the intervention were also assessed.

Eligibility criteria:
inclusion criteria: * adult patients with t2 diabetes who received care at the primary care center * a1c\>7.0% in prior six months exclusion criteria: * age\> 75 * being pregnant * having terminal health condition or other conditions that would impede participation such as dementia and mental illness
we compared the covid-19 acute respiratory distress syndrome (ards) patients who applied prone positioning for16-24 hours vs 24-48 hours

Conditions: Morality; Oxygenation Indices; Hypoxia

Summary: the goal of this study is to understand if there is any improvement on oxygenation of patients diagnosed with covid-19 ards patients when we extend the duration of prone positioning. second outcome of the study is to investigate mortality of patients when we extend the duration of prone positioning.


Eligibility criteria:
inclusion criteria: covi̇d 19 ards patients patients who have been intubated for 48 hours and more exclusion criteria: pediatric patients patients who extubated in less than 48 hours patients with lung and pleural malignancies
prospective multicenter post approval study of the lps-flex mobile bearing knee

Conditions: Osteoarthritis; Traumatic Arthritis; Avascular Necrosis of the Femoral Condyle; Moderate Varus; Valgus; Flexion Deformities

Summary: the purpose of the study is to assess the long-term performance of the nexgen lps-flex mobile bearing knee in the treatment of patients with severe knee pain or degenerative knee disease.

the nexgen lps-flex mobile bearing knee received fda approval for commercial distribution in the us on december 10, 2007. the approval was in accordance with a "condition of approval" to perform a 10-year post approval study to evaluate the longer-term safety and effectiveness of the lps-flex mobile bearing knee. the post approval study will consist of patients from the investigational device exemption study arm (group 1) as well as patients who are eligible for a total knee replacement and have been chosen to receive the lps-flex mobile knee (group 2). group 1 will be followed from 4 years through a total of 10 years from the date of surgery. group 2 will be followed from pre-op through a total of 5 years from the date of surgery.

Eligibility criteria:
inclusion criteria: * osteoarthritis * primary and secondary traumatic arthritis * avascular necrosis of the femoral condyle * moderate varus, valgus, or flexion deformities (i.e. valgus/varus deformity of less than or equal to 15 degrees, fixed flexion deformity of less than or equal to 10 degrees) exclusion criteria: * previous history of infection in the affected joint and/or local/systemic infection that may affect the prosthetic joint * insufficient bone stock on femoral or tibial surfaces * skeletal immaturity * neuropathic arthropathy * osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb * a stable, painless arthrodesis in a satisfactory functional position * severe instability secondary to the absence of collateral integrity * total knee arthroplasty is contraindicated in patients who have rheumatoid arthritis (ra) and an ulcer of the skin or a history of recurrent breakdown of the skin because their risk of postoperative infection is greater. ra patient using steroids may also have increased risk of infection. late infections in ra patients have been reported 24+ months postoperative. * patient is a poor compliance risk, i.e., history of ethanol or drug abuse, or mental handicap that would compromise patient compliance with respect to rehabilitation or follow-up * patient is not willing or able to give informed consent to participate in the follow-up program * patient is not willing to return for all scheduled follow-up appointments as defined by this protocol.

Keywords: arthritis osteoarthritis degenerative knee disease avascular necrosis total knee replacement tka
follow-up of bone quality in long-term bone marrow transplant survivors

Conditions: Osteoporotic Fractures

Summary: brittle and broken bones can occur after organ transplantation. however, the long-term effects of bone marrow transplantation on bone health and the risk of breaking bones are not well understood. this study will help to assess how common it is for those who have received a bone marrow transplant to have fractures. it will also investigate blood tests related to bone health. this will be done by measuring bone mineral density and obtaining blood tests.


Eligibility criteria:
inclusion criteria: * participation in the initial "assessment of skeletal status following allogeneic bone marrow transplantation" study (hsc97-632-408). * able and willing to sign informed consent. exclusion criteria: * all of the contacted long-term bmt survivors that are willing to participate will be included in this study
a simple breath test to detect liver cancer and monitor liver conditions

Conditions: Liver Cirrhosis; Hepatocellular Carcinoma (HCC); Cholangiocarcinoma; Cholangitis, Sclerosing

Summary: liver cancer is often diagnosed too late for effective treatment. the vocal2 study is developing a simple, non-invasive breath test to help detect liver cancer earlier and monitor liver conditions like cirrhosis. the test analyzes tiny chemicals in exhaled breath called volatile organic compounds (vocs) to identify signs of liver disease. who can take part? adults aged 18 or older who: have liver cancer (hepatocellular carcinoma or cholangiocarcinoma), or have liver cirrhosis or primary sclerosing cholangitis, or have tummy symptoms but a normal liver scan. what's involved? participants will: give a breath sample after fasting for 6 hours. answer a few health questions. allow access to relevant medical records. the appointment lasts about 1 hour at an nhs hospital. benefits \& risks this research could lead to an earlier, easier way to detect liver cancer, but there's no direct health benefit for participants. there are no risks, as breath sampling is completely non-invasive and safe. where is the study happening? led by imperial college london, running in nhs hospitals across the uk. who is funding the study? the study is funded by rosetrees and stoneygate trust. contact information email: vocal-study@imperial.ac.uk phone: +44 (0)20 7594 3396


Eligibility criteria:
inclusion criteria: * males and females * adult participants ≥ 18 years old * participants with either: 1. histologically or radiologically-confirmed\* hepatocellular carcinoma or cholangiocarcinoma (participants with liver cancer) 2. liver cirrhosis, confirmed on imaging or histology from biopsy (participants with benign liver disorders) 3. primary sclerosing cholangitis, confirmed on mrcp/ercp or histology from biopsy (participants with benign liver disorders) 4. non-specific gastrointestinal symptoms, but a radiologically-normal liver (healthy controls) exclusion criteria: * active infection, or receiving immunosuppressive medications, within the preceding eight weeks * history of another cancer within the previous five years * previous liver resection * already received chemotherapy, radiotherapy or surgery for their liver cancer * comorbidities preventing breath collection * pregnant women (checked verbally with participant). * unable to provide informed written consent

Keywords: breath liver cancer cirrhosis
urotensin ii and vascular tone in cirrhosis

Conditions: Liver Diseases; Cirrhosis

Summary: this study looks at the iontophoresis of urotensin ii in chronic liver disease patients.


Eligibility criteria:
inclusion criteria: * cirrhosis

Keywords: chronic liver disease
epidemiology of acute bacterial uncomplicated cystitis in general practice

Conditions: Acute Uncomplicated Bacterial Cystitis

Summary: acute uncomplicated bacterial cystitis is common in general practice. cystitis is at the second raw of antibiotic treatment indications. it has been now recommended not to perform any urine culture for more than 20 years; hence, the bacterial epidemiology of acute uncomplicated cystitis is surprisingly relatively unknown. the available bacteriological data mainly describe the epidemiology of complicated urinary tract infections or upper urinary tract infections, but the causative bacteria and the resistance rates might differ from those of uncomplicated cystitis. as an example, it is unknown to what extent staphylococcus saprophyticus is the causative agent of uncomplicated cystitis. moreover, the urine dipstick test have been evaluated in laboratories. but their interpretation in current practice might not be so easy: in particular, the nitrite detection depends on the bacterial concentration. the nitrite detection, produced in enterobacteriaceae related infections might have therapeutical consequences: trométamol-fosfomycine is almost constantly active on enterobacteriaceae, but ineffective on staphylococci. knowing the increasing prevalence of fluoroquinolone-resistant enterobacteriaceae, the use of fosfomycin in nitrite positive uncomplicated cystitis might preserve the susceptibility of fluoroquinolones during pyelonephritis. this study will describe: * the bacterial epidemiology of acute uncomplicated cystitis in general practice, * the correlation in between urine dipstick and urine culture in general practice, * the prediction of enterobacterial infection by the nitrite detection, and * the antibiotics prescribed by the practitioners for uncomplicated acute cystitis.


Eligibility criteria:
inclusion criteria: * female * \>18 years old * urinary symptoms exclusion criteria: * fever * lumbar pain * co-morbidities

Keywords: urinary tract infection cystitis
meal distribution across the day in female nurses working shifts

Conditions: Shift Work Type Circadian Rhythm Sleep Disorder; Imbalance of Constituents of Food Intake

Summary: this study assessed the meal distribution across the day (energy and macronutrient intake) and its relationship to the nutritional status of nursing professionals.

221 female nursing professionals from brazilian university hospital were classified in three shifts: day shift (n=112), night shift (n=55), and day-night shift (n=54). food intake assessment (3-day 24-hour recall); anthropometric variables (weight, height, waist circumference and hip circumference); sleep time on working days and day off.

Eligibility criteria:
inclusion criteria: * eligible participants were regularly employed by the hospital, with 36-hours per week scheduke, not counting additional shifts and overtime work. exclusion criteria: * volunteers who did not supply the necessary information for the development of the research and who were pregnant or lactating.

Keywords: shift work nutritional status nursing professionals meal distribution food intake
clinical evaluation, organic response in obesity patients subjected to vertical videolaparoscopy gastroplasty with or without perioperative cares recommended by the acerto project. randomized study.

Conditions: To Evaluate Clinical Results, Insulin Resistance and Inflammatory Response to Trauma in Morbidly Obese Patients

Summary: background to evaluate clinical results, insulin resistance and inflammatory response to trauma in morbidly obese patients undergoing laparoscopic sleeve gastrectomy who received either traditional preoperative care or treatment following the acerto protocol.

methods the population of the study consisted of morbidly obese patients, who were operated on with the sleeve procedure, from cuiaba, mt, between april and october 2012. we studied the inflammatory response and insulin resistance by measuring levels of glucose, insulin, homa ir, reactive c protein, albumin, pre-albumin, alpha 1 acid glicoprotein, interleukin 6 and glycosylated hemoglobin. we also studied hydration, nausea and vomiting, hypertension, and length of hospital stay.

Eligibility criteria:
inclusion criteria: we included patients who are between 18 and 45 years of age, from both sexes, with an initial bmi (body mass index) which is equal to or greater than 40 kg/m2, candidates for the sleeve surgery procedure through laparoscopy. - exclusion criteria: we excluded the patients who didn't follow the fasting protocol and also those whose laboratory exams were lost. -

Keywords: obesity, morbid insulin resistance acute-phase reaction gastroplasty length of stay protocols randomized controlled trial.
aminophylline to prevent acute kidney injury in children after cardiac surgery

Conditions: Acute Kidney Injury

Summary: children with congenital heart defects often need cardiac surgery with cardiopulmonary bypass (the "heart-lung machine"). approximately 35 to 50% of these children will have "acute kidney injury," or damage to the kidneys, after the procedure. we currently have few medications to prevent this kidney injury. the hypothesis of this study is that giving aminophylline after heart surgery can decrease the acute kidney injury.

patients are randomized to receive aminophylline or placebo for 72 hours, in a blinded fashion. serum theophylline levels monitor for safety of aminophylline dose. goal theophylline levels is 5-7 mcg/ml. laboratory results will be faxed directly to the pharmacy who will adjust subsequent aminophylline dosing to maintain appropriate theophylline levels. urine output and serum creatinine levels will be monitored to assess acute kidney injury. serum neutrophil gelatinase associated lipocalin (ngal) levels will also be monitored.

Eligibility criteria:
inclusion criteria: * less than 18 years old, undergoing cardiac surgery with bypass * neonates must be at least 36 weeks gestational age exclusion criteria: * history of arrythmia or seizure, on extracorporeal membrane oxygenation (ecmo) support, already taking aminophylline/theophylline, liver failure, sepsis, on renal replacement therapy

Keywords: acute kidney injury (aki) cardiopulmonary bypass (cpb)
comparison of treximet & imitrex as they affect the levels of inflammatory markers when the patient is actively having a migraine headache

Conditions: Migraine

Summary: the primary objective is to determine whether inflammatory markers, such as c-reactive protein (crp), calcitonin gene-related peptide (cgrp), vasoactive intestinal polypeptide (vip), or substance p (sp) are reduced in patients having a migraine headache when treated with imitrex or treximet. the secondary objective is to determine the effects of imitrex and treximet on c-reactive protein (crp) in patients with active migraine headaches.

migraine is a neurovascular process involving the brain and related structures. neuroinflammatory substances such as crp, cgrp, vip, sp, and prostaglandins are liberated during the migraine. elevation of these markers may be associated with other conditions which contain an inflammatory component such as coronary artery disease. vip is an inflammation and pain transmission, and thus are markers of sensory nociceptive neurons. during this study, the subjects will have the following inflammation markers analyzed: c-reactive protein (crp), calcitonin gene-related peptide (cgrp), vasoactive intestinal polypeptide (vip), and substance p (sp).

Eligibility criteria:
inclusion criteria: * subject must sign an informed consent * males and females 18 - 65 years of age * have episodic migraine headaches * patients to satisfy the diagnosis of migraine headaches with aura, without aura or mixed * must be able to differentiate migraine headaches from other headaches * diagnosis of migraines for at least 6 months exclusion criteria: * any medical condition, in the opinion of the investigator, that would make the subject unsuitable for enrollment * basilar or hemiplegic migraine headaches * pregnant woman or a nursing mother * history (within 1 year) or current evidence of grug or alcohol abuse * more than 15 migraine headaches per month * chronic daily headache * chronic use of nonsteroidalantiinglammatorydrugs * current participation in a research study or within the last 30 days

Keywords: migraine
arixtra® adherence in svt patients.

Conditions: Thrombosis, Venous

Summary: fondaparinux is an anticoagulant used in the prevention and treatment of thromboembolic disease. it has recently been approved in the european union (eu) for the treatment of patients with isolated superficial vein thrombosis (svt), i.e. without concomitant deep vein thrombosis (dvt), of the lower limbs. as part of eu approval, glaxosmithkline (gsk) committed to evaluate physicians' adherence to fondaparinux prescribing information regarding proper diagnosis and dosing for the treatment of svt. the primary objective is to evaluate physicians' adherence to fondaparinux prescribing information for the treatment of patients with svt without concomitant dvt. the study is designed as a non-interventional, retrospective chart review of patients prescribed fondaparinux to treat their svt. the study will be conducted in several eu countries. arixtra® is a registered trademark of the glaxosmithkline group of companies.


Eligibility criteria:
inclusion criteria: * diagnosis of svt * prescribed fondaparinux for the treatment of svt * age 18 years or older exclusion criteria: * patients should not have been involved in any clinical trial that could influence svt treatment during the observational period.

Keywords: physician adherence superficial vein thrombosis fondaparinux
observational study in preterm neonates who are sufficiently stable on non-invasive ventilatory support

Conditions: Non-invasive Ventilatory Support; Infant Respiratory Distress Syndrome

Summary: the purpose of this observational study is to collect data on vital signs, oxygen requirements and other data related to ventilator care in preterm neonates under standard of care treatment.

the objective of this study is to collect data on vital signs, oxygen requirements and other data in preterm infants who are breathing stably on non-invasive ventilatory support. the data obtained during this study will be used to compare data obtained in a future study that will add a new medicinal product in combination with non-invasive ventilatory support to accelerate lung development in preterm infants. the study will enroll approximately 40 patients. participants will not be receiving any investigational medicinal product or device in this study. all participants will have vital signs, oxygen requirements and other data collected continuously throughout the study. this multi-centre trial will be conducted in germany. the overall time to participate in this study is up to 10 weeks. participants will be observed until they reach 36 weeks of gestational age or until they are discharged from the hospital.

Eligibility criteria:
inclusion criteria: * 1. written, informed consent of both parents or legal guardian(s) obtained (on admission, prior to or after delivery). 2. preterm neonates born at or above 27+0 gestational weeks (gw) who are sufficiently stable on nasal continuous positive airway pressure (cpap). upper limit 36+0 gw. 3. participants' minimum weight at birth must be 800 g. upper weight limit is 2500 g. 4. cpap-positive end-expiratory pressure (peep) must be ≥5 cm and ≤ 8 cm h2o. 5. fraction of oxygen (o2) in ventilator outlet gas flow (fio2) ≥ 30% to reach saturation goal (spo2 between 88% and 96%) during the time period from b0 to t0. exclusion criteria: * 1. fio2 \> 50% to reach saturation goal (saturation of peripheral oxygen (spo2) between 88% and 96%) during the time period from 30 minutes after birth (b0) to 45 minutes after birth (t0). 2. presence of severe respiratory distress syndrome (rds) necessitating immediate intubation and surfactant rescue at entry into the study, or having necessitated surfactant rescue prior to entry into the study. 3. known life-threatening congenital anomaly or genetic syndrome. 4. participation in an interventional study in parallel to this observational study.

Keywords: drug therapy
a study to assess safety and efficacy of umbilical cord-derived mesenchymal stromal cells in knee osteoarthritis

Conditions: Osteoarthritis

Summary: knee-osteoarthritis (oa) is a common and disabling problem, that represents a global health issue since none of the current therapies are truly disease modifying. the use of mesenchymal stem cells (mscs) in oa-preclinical models has been associated with a reduction in cartilage degradation, the attenuation of bone sclerosis and an effective anti-inflammatory response. investigators have designed a randomized phase i/ii placebo controlled trial of uc-mscs in knee oa. outcomes will be evaluated at 12 months, comparing monodosis versus double intra-articular injection, re-randomized at 6 months.


Eligibility criteria:
inclusion criteria: * symptomatic knee oa, kellgren and lawrence grade i, ii, iii on plain rx films. * chondromalacia patella grade i-iii on knee mri. with or without meniscal tear. * stable knee and normal clinical exam of involved extremity * written informed consent for patients. exclusion criteria: * bilateral symptomatic knee oa * local or systemic infection. * active neoplasia or immunosuppressive state * pregnancy or breastfeeding * body mass index ≥ 30 * presence of pacemaker or lower extremity metal implant * anticoagulant treatment other than aspirin. * recent use of oral (previous month) or intra-articular (previous 3 months) corticosteroids * concomitant inflammatory joint disease (cristal, connective tissue disease) * valgus (\>10o) or varus (\>5o) deformity of involved extremity * condilar or tibial plateau generalized bone marrow edema on mri * significant symptomatic hip or spine disease * significant abnormality in baseline lab tests